Premium
Phytoceuticals: Mighty but ignored weapons against Helicobacter pylori infection
Author(s) -
LEE SunYoung,
SHIN Yong Woon,
HAHM KiBaik
Publication year - 2008
Publication title -
journal of digestive diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.684
H-Index - 51
eISSN - 1751-2980
pISSN - 1751-2972
DOI - 10.1111/j.1751-2980.2008.00334.x
Subject(s) - medicine , helicobacter pylori , helicobacter pylori infection , helicobacter infections , microbiology and biotechnology , gastroenterology , biology
Helicobacter pylori ( H. pylori ) infection causes peptic ulcer disease, mucosa‐associated lymphoid tissue (MALT) lymphomas and gastric adenocarcinomas, for which the pathogenesis of chronic gastric inflammation prevails and provides the pathogenic basis. Since the role of H. pylori infection is promoting carcinogenesis rather than acting as a direct carcinogen, as several publications show, eradication alone cannot be the right answer for preventing H. pylori ‐associated gastric cancer. Therefore, a non‐antimicrobial approach has been suggested to attain microbe‐associated cancer prevention through controlling H. pylori ‐related chronic inflammatory processes and mediators responsible for carcinogenesis. Phytoceutical is a term for plant products that are active on biological systems. Phytoceuticals such as Korean red ginseng, green tea, red wine, flavonoids, broccoli sprouts, garlic, probiotics and flavonoids are known to inhibit H. pylori colonization, decrease gastric inflammation by inhibiting cytokine and chemokine release, and repress precancerous changes by inhibiting nuclear factor‐kappa B DNA binding, inducing profuse levels of apoptosis and inhibiting mutagenesis. Even though further unsolved issues are awaited before phytoceuticals are accepted as a standard treatment for H. pylori infection, phytoceuticals can be a mighty weapon for either suppressing or modulating the disease‐associated footprints of H. pylori infection.